Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036921 | 1.00 | DPP4 (0.50) | DPP4F2CYP2D6HTR2ATAAR1 | |
| SCHEMBL3754568 | 1.00 | DPP4 (0.50) | DPP4F2CYP2D6HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL28664928 | 0.97 | DPP4 (0.48) | DPP4F2CYP2D6HTR2ATAAR1 | |
| Ammonia Solution, Strong SCHEMBL28379624 | 0.97 | DPP4 (0.48) | DPP4F2CYP2D6HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL20900097 | 0.97 | DPP4 (0.48) | DPP4F2CYP2D6HTR2ATAAR1 | |
| SCHEMBL5534886 | 0.86 | CHRNB2 (0.47) | DPP4TAAR1 | |
| Hydrochloric Acid SCHEMBL13738816 | 0.83 | TYR (0.33) | — | |
| Hydrochloric Acid SCHEMBL3388587 | 0.77 | DRD1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL2035158 | 0.77 | DRD1 (0.32) | — | |
| SCHEMBL21335077 | 0.77 | DPP4 (0.42) | DPP4F2CYP2D6HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| WO-2015155976-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | 第一三共株式会社 | 2015-10-15 | — | — | WO | disclosed |
| WO-2014151729-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-09-25 | — | — | WO | disclosed |
| WO-2012031228-A2 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-08 | — | — | WO | disclosed |
| US-7884223-B2 | N-isopropylphenethylamine; N-(2,6-dimethoxybenzyl)1-phenethylamine; (R,R) N-(1-naphth-1-ylethyl)-1-phenethylamine; high activity; easily accessible | DSM IP ASSETS B.V. (NL) | 2011-02-08 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-6900322-B1 | Method for stereochemically controlled production of isomerically pure highly substituted azacyclic compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-31 | — | — | US | disclosed |
| EP-1076646-B1 | METHOD FOR STEREOCHEMICALLY CONTROLLED PRODUCTION OF ISOMERICALLY PURE HIGHLY SUBSTITUTED AZACYCLIC COMPOUNDS | SOLVAY PHARM GMBH (DE) | 2004-08-04 | — | — | EP | disclosed |
| EP-1076646-A1 | METHOD FOR STEREOCHEMICALLY CONTROLLED PRODUCTION OF ISOMERICALLY PURE HIGHLY SUBSTITUTED AZACYCLIC COMPOUNDS | Solvay Pharmaceuticals GmbH (DE) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999058500-A1 | METHOD FOR STEREOCHEMICALLY CONTROLLED PRODUCTION OF ISOMERICALLY PURE HIGHLY SUBSTITUTED AZACYCLIC COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | DPP4 26/4885F2 569/4885CYP2D6 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.